StreetInsider.com News Articles

Form 4 Inspire Medical Systems, For: Oct 14 Filed by: Ellis Gary Lee

Fri, 16 Oct 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20261016/27198610.html

Form 4 Inspire Medical Systems, For: Oct 14 Filed by: Melenikiotou Georgia

Fri, 16 Oct 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20261016/27198608.html

Form 4 Inspire Medical Systems, For: Oct 14 Filed by: CARREL MICHAEL H

Fri, 16 Oct 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20261016/27198603.html

Form 4 Inspire Medical Systems, For: Oct 14 Filed by: Broader Shelley G

Fri, 16 Oct 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20261016/27198598.html

Inspire Medical Systems (INSP) PT Raised to $73 at Baird

Thu, 15 Oct 2026 07:22:21 -0400

Baird analyst David Rescott raised the price target on Inspire Medical Systems (NYSE: INSP) to $73.00 (from $59.00) while maintaining a Neutral rating.

Inspire Medical Systems (INSP) PT Raised to $78 at Truist Securities

Wed, 14 Oct 2026 07:00:09 -0400

Truist Securities analyst Richard Newitter raised the price target on Inspire Medical Systems (NYSE: INSP) to $78.00 (from $62.00) while maintaining a Hold rating.

Myomo names new chief commercial officer effective October 2026

Mon, 12 Oct 2026 16:05:17 -0400

Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company based in Burlington, Massachusetts, has appointed Mary-Katherine McClure as Chief Commercial Officer, effective October 12, 2026. She succeeds Micah Mitchell, who will remain with the company through December 23, 2026 to assist with the transition.

McClure joins Myomo from Inspire Medical Systems (NASDAQ: INSP), where she worked since 2018. During her tenure at Inspire, the company's revenues grew from approximately $50 million to nearly $1 billion, and revenues in territories under her leadership grew from $2 million to $150 million. She previously held senior sales roles at Medtronic, Tobii Dynavox, and

Myomo names new chief commercial officer effective October 2026

Mon, 12 Oct 2026 16:05:17 -0400

Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer

Mon, 12 Oct 2026 16:05:00 -0400

BURLINGTON, Mass.--(BUSINESS WIRE)-- Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Mary-Katherine (“Katie”) McClure as Chief Commercial Officer effective October 12, 2026, succeeding Micah Mitchell, who will be departing following a leadership transition period.

Ms. McClure brings more than 20 years of experience in transforming innovative medical technologies into sustainable commercial growth through strategic leadership, talent development, physician engagement, and enterprise partnerships. Ms. McClure joins Myomo from Inspire Medical Systems (“Inspire” NASDAQ:INSP), a fast-growing

Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer

Mon, 12 Oct 2026 16:05:00 -0400

Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer

Mon, 12 Oct 2026 16:05:00 -0400

Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer

Mon, 12 Oct 2026 16:05:00 -0400

Barclays Starts Inspire Medical Systems (INSP) at Underweight

Tue, 06 Oct 2026 16:25:48 -0400

Barclays initiates coverage on Inspire Medical Systems (NYSE: INSP) with a Underweight rating and a price target of $65.00.

For an analyst ratings summary and ratings history on Inspire Medical Systems click here. For more ratings news on Inspire Medical Systems click here.

Shares of Inspire Medical Systems closed at $70.75 yesterday.

Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026

Mon, 05 Oct 2026 16:05:00 -0400

MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2026 after the close of trading on Monday, November 2. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q3 2026 earnings call webcast. For those not planning to ask a question of management, the

Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026

Mon, 05 Oct 2026 16:05:00 -0400

AMA approves new CPT codes for Inspire Medical Systems device

Thu, 01 Oct 2026 16:03:30 -0400

Inspire Medical Systems (NYSE: INSP) announced that the American Medical Association's CPT Editorial Panel has approved a new set of Current Procedural Terminology codes for hypoglossal nerve stimulation, including the company's Inspire V system. The new Category I codes are scheduled to take effect on January 1, 2028.

The codes cover the implantation of a single lead and an implantable pulse generator, addressing procedures performed with the Inspire V system and other single-lead hypoglossal nerve stimulation therapies.

"This new CPT code language addresses the implantation of a single lead and an implantable pulse generator including our recently launched Inspire V system," said

Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel

Thu, 01 Oct 2026 16:03:00 -0400

MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that the American Medical Association (AMA) CPT^® Editorial Panel has approved the establishment of a new set of Current Procedural Terminology (CPT^®) codes that accurately describe and include the Inspire V system. The new Category I codes are scheduled to take effect on January 1, 2028.

“This new CPT code language addresses the implantation of a single lead and

Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel

Thu, 01 Oct 2026 16:03:00 -0400

“This new CPT code language addresses the implantation of a single lead and

Inspire Medical Systems (INSP) PT Raised to $75 at RBC Capital

Thu, 01 Oct 2026 06:52:04 -0400

RBC Capital analyst Shagun Singh raised the price target on Inspire Medical Systems (NYSE: INSP) to $75.00 (from $60.00) while maintaining a Sector Perform rating.

Inspire Medical Systems (INSP) PT Raised to $80 at Stifel

Fri, 11 Sep 2026 09:26:14 -0400

(Updated - September 11, 2026 9:26 AM EDT)

Stifel analyst Jonathan Block raised the price target on Inspire Medical Systems (NYSE: INSP) to $80.00 (from $75.00) while maintaining a Buy rating.

The analyst commented, "While our November 2025 upgrade was initially derailed by a volatile reimbursement environment, which led to several negative revisions to 2026 guidance, our diligence at the June Sleep conference suggested that the worst was behind Inspire with green shoots starting to emerge. Inspire followed with 2Q26 results ahead of consensus and the midpoint of 2026 guidance was revised slightly higher. The stock has responded since June lows, and

Inspire Medical Systems (INSP) PT Raised to $80 at Stifel

Fri, 11 Sep 2026 09:26:14 -0400

(Updated - September 11, 2026 9:26 AM EDT)

Stifel analyst Jonathan Block raised the price target on Inspire Medical Systems (NYSE: INSP) to $80.00 (from $75.00) while maintaining a Buy rating.

Form 4 Inspire Medical Systems, For: Aug 31 Filed by: Kelly Jason P

Wed, 02 Sep 2026 20:29:00 -0400

si-local-file:///var/storage/secattach/20260902/27020731.html

Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

Wed, 26 Aug 2026 09:15:00 -0400

MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Wells Fargo 21^st Annual Healthcare Conference on Wednesday, September 9, 2026.

Inspire is scheduled to present at 1:30 p.m. Eastern Time. The presentation will be accessible via a live webcast here.

A webcast replay of the presentation will be available for two weeks following the presentation in the

Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

Wed, 26 Aug 2026 09:15:00 -0400

Inspire is scheduled to present at 1:30 p.m. Eastern Time. The presentation will be accessible via a live webcast here.

A webcast replay of the presentation will be available for two weeks following the presentation in the

Form 144 Inspire Medical Systems, Filed by: Rondoni John

Mon, 24 Aug 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260824/26968460.html